Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00109642 · ClinicalTrials.gov registry record

The Role of Norepinephrine in Emotional Processing

A clinical trial of Mental Disorders and Psychopathy, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
216
Enrollment target
1
Study location

NCT00109642 is a study of Mental Disorders and Psychopathy that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 216 participants, below the 676-participant average among 25 other Mental Disorders trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00109642, a study of Mental Disorders and Psychopathy, has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
216 participants
Enrollment target
1
Study location

Study Summary

This study will examine the role of a brain chemical called norepinephrine in thinking, decision-making, and emotional processing. After norepinephrine is released from a brain cell, it binds to another brain cell's receptor. Some of the receptors it binds to are called alpha-2 adrenergic receptors. This study will use medicines called yohimbine and guanfacine to look at the function of norepinephrine in the brain when it binds to the alpha-2 adrenergic receptors. Yohimbine increases norepinephrine's function and guanfacine decreases its function. Healthy volunteers between 20 and 50 years of age who do not have heart disease, high blood pressure, psychiatric illness, or other serious medical conditions and who are not allergic to lactose may be eligible for this study. Candidates are screened with a medical and psychiatric history, physical examination, neuropsychological testing, blood and urine tests and electrocardiogram. Women are screened with a urine pregnancy test. Participants are given a pill of yohimbine, guanfacine, or placebo and undergo the following tests and procedures: * Blood pressure and heart rate measurements: Blood pressure and heart rate are measured before the medication is taken and several times after. * Blood draws: Blood is drawn before the medicine is taken and 90 minutes after to measure levels of norepinephrine and the hormone cortisol. * Neurocognitive testing: Participants do neurocognitive tasks on the computer for up to 90 minutes. The tasks involve looking at pictures or words on a screen and responding according to instructions given. * Magnetic resonance imaging (MRI): Patients may undergo neurocognitive testing MRIs. This test uses a strong magnetic field and radio waves to show changes in brain activity. The subject lies on a table that slides into a narrow cylinder (the MRI scanner). Images of the brain are obtained while the subject performs the computer tasks.

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 216 participants
Start Date 2005-04-26
Est. Completion 2009-03-15

What the Registry Record Tells You About NCT00109642

The ClinicalTrials.gov registry entry for NCT00109642 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 676-participant average among 25 other Mental Disorders trials with a reported enrollment target (68% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Mental Disorders appearing as the primary indexed condition, and to 0 interventions.

NCT00109642 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00109642 about?

NCT00109642 is a clinical study titled "The Role of Norepinephrine in Emotional Processing". This study will examine the role of a brain chemical called norepinephrine in thinking, decision-making, and emotional processing. After norepinephrine is released from a brain cell, it binds to another brain cell's receptor. Some of the receptors it binds to are called alpha-2 adrenergic receptors....

What is the current status of trial NCT00109642?

This trial is currently completed. The enrollment target is 216 participants. The study started on 2005-04-26. Estimated completion is 2009-03-15.

What conditions does trial NCT00109642 study?

This clinical trial studies the following conditions: Mental Disorders, Psychopathy.

Who is sponsoring clinical trial NCT00109642?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00109642 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mental Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.